EVERDIUM
LIVE

Serial Number

79402827

Owner

Bausch Health Ireland Limited

Attorney

Jeremy Blackowicz

Filing Date

Apr 9, 2024

Add to watchlist:

No watchlists yet
View on USPTO

EVERDIUM Trademark

Serial Number: 79402827 • Registration: 7674485

EVERDIUM is a trademark filed by Bausch Health Ireland Limited on April 9, 2024. The trademark is classified under Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Bausch Health Ireland Limited

3013 Lake Drive Citywest Business Campus

Entity Type: 99

Trademark Details

Filing Date

April 9, 2024

Registration Date

February 4, 2025

Published for Opposition

December 17, 2024

Goods & Services

Surgical apparatus and instruments; medical apparatus for the delivery and release of pharmaceuticals, namely, drug delivery patches sold without medication, inhalers for medical use sold empty, intravenous bags sold empty for intravenous therapy, syringes; medical apparatus for facilitating the inhalation of pharmaceutical preparations; medical apparatus for the treatment of respiratory conditions; medical diagnostic apparatus for medical purposes for testing of blood sugar levels, respiratory health, liver function, kidney function, viruses, cancer cells, DNA, antibody levels; medical devices for non-surgical cosmetic skin treatments; lasers for the medical and cosmetic treatment of the face and skin; radiofrequency apparatus for the medical and cosmetic treatment of the face and skin; high frequency electromagnetic wave therapeutic instruments; medical devices and equipment for liposuction; apparatus for the treatment of cellulite; medical apparatus and instruments using radiofrequency energy for body toning and body shaping; apparatus for non-invasive surgery, namely for body toning and body shaping; medical apparatus generating electromagnetic, magnetic, electrical, mechanical or thermal energy for the therapeutic stimulation of the body

Pharmaceutical products and medicines for human use for the prevention and treatment of allergies; Pharmaceutical products and medicines for human use for the prevention and treatment of autoimmune conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of blood conditions, diseases and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of cardiovascular diseases and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of conditions, diseases, and disorders of the central and peripheral nervous system; Pharmaceutical products and medicines for human use for the prevention and treatment of dermatological conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of endocrine conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of gastrointestinal conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of hepatic conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of immunological conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of infectious diseases; Pharmaceutical products and medicines for human use for the prevention and treatment of inflammatory conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of metabolic conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of neurological conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of pain; Pharmaceutical products and medicines for human use for the prevention and treatment of psychiatric conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of respiratory and pulmonary conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of renal conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of urological conditions, diseases, and disorders; Pharmaceutical products and medicines for human use for the prevention and treatment of viral diseases; Pharmaceutical products and medicines for human use, namely, antibiotics; Pharmaceutical products and medicines for human use, namely, medicated beverages, powders, and gels for colonoscopies and endoscopic procedures; medicated skin care preparations; medicated oral care preparations, namely mouthwash, dental rinses; nutritional supplements; dietary supplements; vitamins; diagnostic preparations for medical purposes

Providing medical information; providing health information; consultancy and medical information services relating to medical products; providing medical and health information and treatment support programs to consumers and healthcare professionals regarding pharmaceutical products; medical services, namely, providing medical information regarding prescription drugs and disease prevention, diagnosis, screening, and treatment; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; providing medical and health information in the field of illness and disease prevention, screening, diagnosis, and treatment; providing medical and health information and treatment support programs to consumers and healthcare professionals regarding medical aesthetics treatments and procedures; providing medical and health information to consumers and healthcare professionals regarding dental treatment, dental hygiene, and oral health; medical testing services relating to the diagnosis and treatment of illness and disease; providing information in the fields of health and wellness; cosmetic facial and body treatment services; non-invasive cosmetic medical services; aesthetic and therapeutic skin and body treatment services; laser skin rejuvenation service; laser skin tightening service; medical treatment services, namely energy-based procedures for treatment of the face, body, tissue and skin

Non-medicated skin care preparations; non-medicated oral care preparations, namely, toothpaste, mouthwash, dental rinse; oral hygiene preparations, namely, toothpaste, mouthwash, dental rinse; cosmetics

Pharmaceutical research and development; research and development services relating to medicines; conducting clinical trials for others for pharmaceutical products; testing of pharmaceuticals; medical and scientific research and analysis for the prevention, diagnosis, treatment and management of illness and disease; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; conducting early evaluations in the field of new pharmaceuticals; pharmaceutical drug delivery system development services; product research and development in the field of beauty, wellness, and health care products

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Feb 5, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 21, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jan 21, 2026 OPNR
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 5, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 19, 2025 FICS
FINAL DISPOSITION PROCESSED
Aug 19, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 5, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 4, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 4, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 17, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 17, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 11, 2024 NONP
REFUSAL PROCESSED BY IB
Nov 23, 2024 RFNT
NEW REPRESENTATIVE AT IB RECEIVED
Nov 22, 2024 NREP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 20, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 20, 2024 XAEC
ASSIGNED TO LIE
Nov 19, 2024 ALIE
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 19, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 19, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 19, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 8, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 8, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 8, 2024 TROA
NEW REPRESENTATIVE AT IB RECEIVED
Nov 1, 2024 NREP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 8, 2024 RFCS
REFUSAL PROCESSED BY MPU
Oct 8, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 3, 2024 RFCR
NON-FINAL ACTION WRITTEN
Oct 2, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 26, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 6, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 6, 2024 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 22, 2024 REPR